Frequency of detecting markers of hepatitis C among the conditionally healthy population of Tatarstan Republic


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Population studies are important for understanding the full epidemiological situation in certain regions of Russia, and obtained data should be taken into account when creating regional screening programs for hepatitis C virus (HCV) detection. The aim of the study is to determine the true prevalence of HCV markers among the apparently healthy population of Tatarstan Republic (RT). Material and methods. 913 samples of blood sera from a conditionally healthy population of Tatarstan Republic were studied. The sample included persons of 9 age groups: under one year old, 1-9 years old, 10-14 years old, 15-19 years old, 20-29 years old, 30-39 years old, 40-49 years old, 50-59 years old and over 60 years old. The presence of antibodies to the virus in the samples was checked by EIA methodic in screening and confirmatory test. All anti-HCV positive participants were screened for the presence of an ongoing infectious process by detecting HCV RNA by means of RT-PCR methodic. In samples positive for HCV RNA, the genotype of the virus was also fixed. Results. Anti-HCV detection rates in average consisted of 2.1% (19/913; 95% CI: 1,3-3,2%), and the prevalence of current infection confirmed by HCV RNA detection was 0,9% (8/913; 95 % CI: 0,4-1,7%). In age cohorts over 60 and 30-39 years old, there were significant differences in the incidence of HCV RNA comparatively with other study groups, the analyzed index was 3,4% (4/119; 95% CI: 1,0-8,6%) and 2,7% (3/112; 95% CI: 0,5-7,9%), respectively. Phylogenetic analysis showed the division of the studied HCV isolates into subtypes 1a (n=1), 1b (n=2), 2a (n=2) and 3a (n=3). Conclusion. In general, among the conditionally healthy population of Tatarstan Republic, an average level of prevalence of HCV infection was revealed. Individuals aged 30-39 years and older than 60 years are the cohorts in which more careful monitoring of the spread of HCV is needed, while the presence of risk factors for infection is an index of less diagnostical importance.

Full Text

Restricted Access

About the authors

Vera S. Kichatova

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: vera_kichatova@mail.ru
PhD in Medicine, researcher at the Laboratory of viral hepatitis

Karen K. Kyuregyan

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia; Peoples' Friendship University of Russia

Email: karen-kyuregyan@yandex.ru
Dr. habil. biol., professor of RAS, chief researcher at Research Institute of Molecular and Personalized Medicine

Anastasia A. Carlsen

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Peoples' Friendship University of Russia

Email: karlsen12@gmail.com
researcher at Research and Educational Resource Center «High-Performance Methods of Genomic Analysis»

Ilya A. Potemkin

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: axi0ma@mail.ru
PhD in Medicine, researcher at the Department of viral hepatitis studies, Research Institute of Molecular and Personalized Medicine

Fedor A. Asadi Mobarkhan

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: 1amfa@bk.ru
researcher at the Department of viral hepatitis studies, Research Institute of Molecular and Personalized Medicine; researcher at the Laboratory of viral hepatitis

Olga V. Isaeva

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: isaeva.06@mail.ru
PhD in Biology, leading researcher at the Department of viral hepatitis studies; leading researcher at the Laboratory of viral hepatitis

Maria A. Lopatukhina

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums

Email: m.lopatukhina@gmail.com
researcher at the Laboratory of viral hepatitis

Elena Yu. Malinnikova

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: malinacgb@mail.ru
Dr. med. habil., professor, head of the Department of virology; leading researcher at the Laboratory of viral hepatitis

Irina E. Kravchenko

Kazan State Medical University of the Ministry of Healthcare of Russia

Email: kravchencoie@mail.ru
Dr. med. habil., professor of the Department of infectious diseases

Olga O. Znoyko

A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: olgaznoyko@yandex.ru
Dr. med. habil., professor of the Department of infectious diseases and epidemiology

Nikolai D. Yuschuk

A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Dr. med. habil., professor, academician of RAS, president

Mikhail I. Mikhailov

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: michmich2@yandex.ru
Dr. med. habil., professor, corresponding member of RAS, scientific director of Research Institute of Molecular and Personalized Medicine; head of the Laboratory of viral hepatitis

References

  1. Global health sector strategy on viral hepatitis 2016-2021. WHO, Geneva. 2016. URL: http://apps.who.int/iris/bitstream/10665/246177/1/ WHO-HIV-2016.06-eng.pdf?ua=1 (date of access - 10.04.2022).
  2. Кравченко И.Э., Гинятуллин Р.Р., Амон Е.П., Малинникова Е.Ю. Состояние медицинской помощи больным хроническим гепатитом С. в Российской Федерации. Инфекционные болезни: новости, мнения, обучение. 2019; 4: 48-57. https://dx.doi.org/10.24411/2305-3496-2019-14007.
  3. Ющук Н.Д. Рекомендации по диагностике и лечению взрослых больных гепатитом С. 3-е изд., испр. и доп. М.: ГЭОТАР-Медиа. 2017; 96 с. ISBN 978-5-9704-4270-8.
  4. Вирусные гепатиты в Российской Федерации. Аналитический обзор. 11 выпуск. Под ред. В.И. Покровского, А.А. Тотоляна. СПб.: ФБУН НИИЭМ им. Пастера. 2018; 112 с.
  5. Соболева Н.В., Карлсен А.А., Кожанова Т.В. с соавт. Распространенность вируса гепатита С. среди условно здорового населения Российской Федерации. Журнал инфектологии. 2017; 2: 56-64. https://dx.doi.org/10.22625/2072-6732-2017-9-2-56-64.
  6. Кюрегян К.К., Исаева О.В., Кичатова В.С. с соавт. Распространенность маркеров гепатитов В. и С. среди условно здорового населения Калининградской области. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2020; 4: 13-20. https://dx.doi.org/10.18565/epidem.2020.10.4.13-20.
  7. Росстат. Оценка численности постоянного населения на 1 января 2020 года и в среднем за 2019 год. Доступ: https://rosstat.gov.ru (дата обращения - 10.04.2022).
  8. WHO guidelines on hepatitis B. and C. testing. Geneva: WHO, 2017. Licence: CC BY-NC-SA 3.0 IGO. ISBN: 978-92-4-154998-1.
  9. Кюрегян К.К., Соболева Н.В., Карлсен А.А. с соавт. Динамические изменения распространенности вируса гепатита С. среди населения Республики Саха (Якутия) за последние 10 лет. Инфекционные болезни: новости, мнения, обучение. 2019; 2: 16-26. https://dx.doi.org/10.24411/2305-3496-2019-12002.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies